NCT06596122View on ClinicalTrials.gov

Vitamin D Supplementation in Breast Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 30, 2026

Conditions

Peripheral Neuropathic Pain

Interventions

DRUG

Vitamin D (Cholecalciferol )

In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.

Trial Locations (1)

Unknown

Ain Shams University (El-Demerdash) Hospital, Cairo

All Listed Sponsors

lead

Abdelrahman Mahmoud

OTHER

NCT06596122 - Vitamin D Supplementation in Breast Cancer Patients | Biotech Hunter | Biotech Hunter